Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function
- 19 June 2013
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 15 (12) , 1101-1110
Abstract
Aims: The effects of sitagliptin and pioglitazone, alone and in combination, on α ‐ and β‐cell function were assessed in patients with type 2 diabetes. Methods: Following a 6‐week diet/exercise period, 211 patients with HbA1c of 6.5–9.0% and fasting plasma glucose of 7.2–14.4 mmol/l were randomized (1 :1 :1 : 1) to sitagliptin, pioglitazone, sitagliptin + pioglitazone or placebo. At baseline and after 12 weeks, patients were given a mixed meal followed by frequent blood sampling for measurements of glucose, insulin, C‐peptide and glucagon. Results: After 12 weeks, 5‐h glucose total area under the curve ( AUC ) decreased in all active treatments versus placebo; reduction with sitagliptin + pioglitazone was greater versus either monotherapy. The 5‐h insulin total AUC increased with sitagliptin versus all other treatments and increased with sitagliptin + pioglitazone versus pioglitazone. The 3‐h glucagon AUC decreased with sitagliptin versus placebo and decreased with sitagliptin + pioglitazone versus pioglitazone or placebo. Φ s , a measure of dynamic β‐cell responsiveness to above‐basal glucose concentrations, increased with either monotherapy versus placebo and increased with sitagliptin + pioglitazone versus either monotherapy. The insulin sensitivity index ( ISI ), a composite index of insulin sensitivity, improved with pioglitazone and sitagliptin + pioglitazone versus placebo. The disposition index, a measure of the relationship between β‐cell function and insulin sensitivity, improved with all active treatments versus placebo. Conclusions: Sitagliptin and pioglitazone enhanced β‐cell function (increasing postmeal Φ s ), and sitagliptin improved α ‐cell function (decreasing postmeal glucagon) after 12 weeks in patients with type 2 diabetes. Through these complementary mechanisms of action, the combination of sitagliptin and pioglitazone reduced postmeal glucose more than either treatment alone.Keywords
This publication has 45 references indexed in Scilit:
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered ApproachDiabetes Care, 2012
- Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial with an open‐label long‐term extension studyDiabetes, Obesity and Metabolism, 2011
- Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event ReportingDiabetes Care, 2011
- Risk of Bladder Cancer Among Diabetic Patients Treated With PioglitazoneDiabetes Care, 2011
- Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 DiabetesDiabetes Care, 2010
- Long‐term glycaemic effects of pioglitazone compared with placebo as add‐on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18)Diabetic Medicine, 2009
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled studyCurrent Medical Research and Opinion, 2009
- Assessment of β-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose testsAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for Type 2 diabetesExpert Opinion on Investigational Drugs, 2007
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitusDiabetologia, 2006